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ABSTRACT: Objective: The behavioral effects of two therapeutic ivermectin (IVM) doses 
administered in the juvenile period of male and female rats, submitted or not to stress, were 
observed. The open field and elevated plus maze tests were employed. Methods: Male and 
female rats that were 29 and 45 days of age were divided in six groups: two controls groups 
injected with the control solution and four experimental groups injected with 0.2 or 1.0 mg/kg 
of IVM.  Twenty-four hours after the last treatments, only half of these rats were submitted to 
stress and all groups observed in the open field and elevated plus maze. The plasmatic 
corticosterone levels were measured in stressed and non-stressed rats.  Results: 1) 0.2 
mg/kg IVM did not affected the sexual dimorphism in the open field and elevated plus maze 
tests but, the 1.0 mg/kg dose disrupt the sexual dimorphism in both tests; 2) only females 
treated with the high dose of ivermectin showed increased levels of plasmatic corticosterone 
levels; 3) stress only impaired the  sexual dimorphism in the elevated plus maze, 4) no 
differences were observed in the plasmatic levels of corticosterone between all groups 
exposed to stress. Conclusions: IVM high dose disrupt the sexual dimorphism in the open 
field and elevated plus maze behaviors in the juvenile period. Stress disrupts the sexual 
dimorphism only in the elevated plus maze, mainly in female rats. These data suggest that 
female rats were more sensible to IVM, particularly related to anxiety behavior. 
Keywords: avermectin, restraint stress,  open field, elevated plus maze, rats, behavior 
 
RESUMO: Objetivo: foram observados os efeitos comportamentais das doses terapêuticas 
de ivermectina (IVM) administradas no período juvenil de ratos machos e fêmeas, 
submetidos ou não ao estresse. Foram utilizados os testes de campo aberto e labirinto 
elevado. Métodos: ratos machos e fêmeas com idade entre 29 e 45 dias foram divididos em 
seis grupos: dois grupos  controle foram injetados com a solução de controle e quatro 
grupos experimentais injetados com 0,2 ou 1,0 mg / kg de IVM. Vinte e quatro horas após 
os últimos tratamentos, metade desses ratos foram submetidos ao estresse e a outra 
metade não sendo todos os grupos observados no campo aberto e labirinto em cruz 
elevado. Os níveis plasmáticos de corticosterona foram medidos em ratos estressados e 
não estressados. Resultados: 1) 0,2 mg / kg IVM não afetou o dimorfismo sexual em campo 
aberto e teste de labirinto  elevado, mas a dose de 1,0 mg / kg prejudicou o dimorfismo 
sexual em ambos os testes; 2) apenas as fêmeas tratadas com a maior dose de 
ivermectina apresentaram maiores níveis plasmáticos de corticosterona; 3) o estresse 
prejudicou apenas o dimorfismo sexual no labirinto elevado, 4) não foram observadas 
diferenças nos níveis plasmáticos de corticosterona entre todos os grupos expostos ao 
estresse. Conclusões: A maior dose de IVM prejudicou o dimorfismo sexual no campo 
aberto e os comportamentos no labirinto em cruz elevado no período juvenil,  
principalmente nas fêmeas. Esses dados sugerem que as fêmeas foram mais sensíveis à 
IVM, em comportamento relacionados à ansiedade. 
Palavras-chave: avermectinas, estresse por contenção, campo aberto, labirinto em cruz 
elevado, ratos, comportamento. 
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INTRODUCTION
 
Avermectins are broad-spectrum 
antiparasitic agents that are widely used 
in agricultural, and domestic animals 
(BLOOMQUIST, 2003) (CASIDA; 
DURKIN, 2013) Campbell, 2016). In 
human clinical practice, avermectins is 
used to treat lymphatic filariasis, 
onchocerciases, rosacea, scabies, head 
lice  and others (KIRCIK et al., 2016). 
Ivermectin (IVM) belongs to the 
macrocyclic lactone class of 
endectocides and consists of a mixture 
of two homologous compounds, 22, 23-
dihydroavermectin B1a (H2B1a; not 
b80%) and 22,23-dihydroavermectin B1b 
(H2B1b; not N20%). In vertebrates, IVM, 
the first macrocyclic lactone synthesized 
avermectin (ELGART; MEINKING, 
2003), can produce γ-aminobutyric acid 
(GABA)-mimetic effects by acting as 
agonists at GABA receptors and 
stimulating GABA release (DAWSON et 
al., 2000; ESTRADA-MONDRAGON; 
LYNCH, 2015; SHOOP; MROZIK; 
FISHER, 1995). Mammals are less 
susceptible to the toxic effects of 
macrocyclic lactones because GABA-
mediated nerves occur only in the central 
nervous system (CNS), and macrocyclic 
lactones do not readily cross the blood-
brain barrier (YANG, 2012) 
Previously, we found that IVM at 
therapeutic dose (0.2 mg/kg) did not alter 
male rat sexual behavior. However, at a 
higher dose (0.6 mg/kg) the appetitive 
phase of sexual behavior in 
inexperienced male rats was impaired 
(BERNARDI et al., 2011).  The effects of 
therapeutic and high (1.0 mg/kg) IVM 
doses were also studied in female rat 
sexual behavior in physiological and 
pharmacological conditions. We 
observed that in both hormonal 
conditions, 0.2 mg/kg IVM treatment 
reduced female sexual behavior and the 
execution of the lordosis 
reflex(MOREIRA; BERNARDI; 
SPINOSA, 2014).  In addition, other  
studies  performed in our laboratory 
demonstrated that IVM act as GABAergic 
agonists and interferes with GABAergic-
related behavior, reducing anxiety-like 
behavior and seizures (DE SOUZA 
SPINOSA; STILCK; BERNARDI, 2002). 
However, no studies were 
performed in male and female rats 
treated with IVM in the juvenile period on 
exploratory/motor and anxiety behaviors. 
Because male and female rats has 
different susceptibility to stress 
(BANGASSER; WICKS, 2017), also the 
behavioral IVM effects and the plasmatic 
corticosterone levels were observed after 
restraint stress .  
The period of exposure to IVM was 
chosen because this drug is used for 
therapeutic purposes in children who are 
in a period of hormonal and brain 
maturation. In addition, in several cases, 
the effects upon rats were studied only in 
males or only in females and these 
variables may be of importance since 
several modalities of behavior differ 
qualitatively and quantitatively in male 
and female rats (FONSECA; SELL; 
CARLINI, 1976;ROMEO et al., 2016).  
 
MATERIAL AND METHODS 
 
Animals 
Male and female Wistar rats 29 
days old (male- 88.11± 3.29 g, female- 
76.67 ±3.27 g) at the beginning of 
experiments (Department of Pathology, 
School of Veterinary Medicine and 
Animal Science, University of São Paulo, 
Brazil) were used. The animals were 
housed in polypropylene cages (40 × 50 
× 20 cm) at a controlled temperature of 
(20 ± 21 °C) and humidity of (60 ± 5%) 
under a controlled light/dark schedule 
(12 h light/12 h dark), with lights on at 
10:00 AM for at least 7 days before the 
experiments. Food (Nuvilab CR1, 
species-specific ration; Sogorb Ind & 
Com Ltd, São Paulo, São Paulo, Brazil) 
and water (filtered in porcelain) were 
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freely available throughout the study. All 
of the procedures were reviewed and 
approved by the Animal Care Committee 
FMVZ-USP (protocol no. 2881/2013) and 
conformed with the guidelines of the 
Committee on Care and Use of 
Laboratory Animal Resources, National 
Research Council, USA(COMMITTEE, 
2011). 
 
Drugs 
Ivermectin 1% Ivomec injectable, 
Merial, Paulinia, São Paulo, Brazil) was 
dissolved in Tween 80 (1 drop/1 ml of 
1% Ivomec) and administered 
subcutaneous (s.c.) at a dose of 0.2 or 
1.0 mg/kg. Tween 80 was also 
administered in the same form as a 
control solution       (1 drop/1 ml of 0.9% 
NaCl). All of the solutions were prepared 
immediately before use and administered 
in a volume of 1 ml/kg body weight. 
 
Procedures 
 
General activity in the open field 
An open field (OF) was used to 
assess the effects of the extract on 
emotionality and motility and constructed 
according to Broadhurst (1957). The OF 
apparatus was a white circular wooden 
arena based on (FAGGIN; PALERMO-
NETO, 1985). The floor of the arena was 
divided into three concentric circles that 
were divided into 19 straight segments 
with equal areas. The circular wooden 
arena was enclosed inside a wooden 
case, 48 cm above the floor. The 
apparatus was placed in a sound-
attenuated room with dim light (55 lx at 
the OF arena). In the OF test, each 
animal was placed in the center of the 
arena and observed for 5 min. The 
animals in the control and experimental 
groups were alternately observed during 
the light phase of the light/dark cycle 
between 9:00 AM and 11:00 AM. The OF 
was cleaned with a 5% alcohol solution 
between sessions to remove any odors. 
We evaluated the total frequency of 
locomotion, the peripheral locomotion 
and duration of immobility. One unit of 
locomotion was defined as the animal 
entering one area of the arena floor with 
all four paws. Immobility was defined as 
the length of time (in seconds) during 
which the animal did not engage in any 
motor activity (i.e., the head, trunk, and 
limbs were still).  
 
Elevated-plus maze 
Elevated-plus maze (EPM) is an 
apparatus first conceived by the British 
psychologist Sheila Handley’s group as a 
model to evaluate anxiety and it is one of 
the most used for that purpose 
(PELLOW et al., 1985). The EPM device 
used was made of wood and had two 
open arms (23.5 cm × 8 cm) and two 
enclosed arms of the same size with 20 
cm high walls; the apparatus was 
elevated 80 cm above the ground, it was 
placed in a sound-proof room with room 
lamp of 100W (at the floor of apparatus 
400 lx). Basically, two strategies can be 
easily noticed: avoidance of the open 
arms while staying in the closed arm and 
escape from the open arm directly to the 
closed arm (PELLOW et al., 1985). In the 
present study, the apparatus was used to 
assess anxiety, and the animals were 
assayed after being tested in the OF. 
The animals were allocated in the center 
of the maze, which was previously 
cleaned with 5% alcohol and observed 
during 3 min. Exploratory behavior was 
determined by the number of crosses in 
the center of the EPM. The time and 
entries in open arms and the risk 
assessment were employed to evaluate 
the anxiety-like behavior.  
 
Stress Induction (New York Subway 
System). 
The stress model of the New York 
subway system was described by 
Dhabhar&. McEwen (DHABHAR; 
MCEWEN, 1997) , whose laboratory is 
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located in New York. It was named 
because it resembles the situation 
experienced by an individual boarding 
the subway during a time of great 
movement of users: restricted capacity to 
move the body and continuous shaking. 
The apparatus to restrict movement 
consists of a wood laminated board (23.5 
cm length) to which six polyvinyl chloride 
(PVC) pipes (3 cm diameter x 10 cm 
length) are attached to restrict the 
movement of individuals. The pipes have 
closed ends to prevent escape, but with 
holes at the front for rear ventilation and 
allowing passage of the tail. To induce 
the New York subway stress, the 
apparatus was placed on a mechanical 
shaker (Shaker Kline – Nova Ética, 
Model 108, Vargem Grande Paulista), 
set to 1 vibration/second. We exposed 
the rats to 1 hour of stress, during which 
the animals had no access to acid 
solution or feed. Animals were subjected 
to 1h of stress at 45 days old.  
 
Corticosterone plasmatic levels 
The blood was collected in conical 
tubes that contained 10% 
Ethylenediaminetetraacetic acid. The 
samples were centrifuged, and plasma 
was obtained. Plasma samples from 
each animal were aliquoted in several 
conical tubes for analyses (in duplicate) 
of corticosterone using commercial 
enzyme-linked immunosorbent assay kits 
according to the manufacturer’s 
instructions.  Corticosterone levels were 
determined using an Arbor Assays kit 
(catalog no. K014-H5, Ann Arbor, MI, 
USA). The results are expressed as 
ng/ml. 
 
Experimental design  
Forty-two male and forty-two female 
rats 29 days old were divided into six 
groups. The following groups were 
formed: 1) control male and control 
female groups injected with the control 
solution (n=14/group); 2) experimental 
male and female groups injected with 0.2 
mg/kg of IVM (n=14/group); 3) 
experimental male and female groups 
injected with              1.0 mg/kg of IVM 
(n=14/group).  At 44 days old these 
treatments were repeated and 24 h after, 
1) half of these rats were observed in the 
OF and EPM; 2)the other half of rats 
were submitted to 1 h of stress and also 
observed in the OF and EPM. 
Immediately after the EPM, the rat trunk 
blood was collected to evaluate the 
corticosterone levels. 
 
Statistical analysis 
 Homogeneity was verified using 
Bartlett’s test. Normality was verified 
using the Kolmogorov-Smirnov test. 
Two-way analysis of variance (ANOVA) 
followed by Bonferroni’s multiple-
comparison test was used to compare 
the data. The results are expressed as 
the mean ± SEM. In all cases, the results 
were considered significant at p < 0.05. 
  
RESULTS 
 
Effects of IVM treatment in male and 
female rats not exposed to stress.  
 Fig.1 shows the general activity of 
male and female rats treated with 0.2 or 
1.0 of IVM in the juvenile age observed 
in the OF at 45 days age.   
Concerning the total locomotion 
(fig.1A) the two way ANOVA did not 
show interaction between sex and 
treatments (F2, 36 =0.82, p =0.45), the 
sex influenced the results (F1,36=23.3, 
p<0.0001) but not the treatments 
(F2,36=2.15,p=0.13). The Bonferroni test 
indicates an increased total locomotion in 
female of control and 0.2 mg/kg IVM 
relative to control and 0.2 mg/kg IVM 
groups of males, respectively. No 
differences were observed between male 
and female treated with 1.0 mg/kg of 
IVM.  
In peripheral locomotion (fig.1B) the 
two way ANOVA did not show interaction 
between sex and treatments 
(F2,36=0.68,p=0.52), the sex influenced 
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the results (F 1,36=6.91, p<0.01) but not 
the treatments (F2,36=2.67,p=0.08). The 
Bonferroni test indicates an increased 
peripheral locomotion in female of control 
group relative to control males. No 
differences were observed between male 
and female treated with both IVM doses. 
Relative to immobility (fig.1C) no 
interaction between sex and treatments 
(F2,36=2.03,p=0.15) was observed; the 
sex influenced the results (F1,36=8.42, 
p<0.006) but not the treatments 
(F2,36=1.45,p=0.25). The Bonferroni test 
indicates a decreased immobility in 
female of control group relative to control 
males. No differences were observed 
between male and female treated with 
both IVM doses. 
 
  
Figure 1- General Activity of male and female 
rats treated with 0.2 or 1.0 of IVM in the juvenile 
age observed in the open field at 45 days age.  
A- Total locomotion frequency; B-peripheral 
locomotion frequency; C- immobility duration 
(sec). Data are presented as means ± SEM. 
N=7/group. Two way ANOVA followed by the 
Bonferroni test. *p<0.05, ***p<0.0001, relative to 
the male rat of the same treatment.  
 
Fig.2 illustrates the effects of IVM 
treatment in male and female rats 
observed in the EPM at 45 days of age.  
 Relative to time in open arms 
(fig.2A), no interaction between sex and 
treatments (F2,36=1.08,p=0.35) and 
between treatments 
(F2,36=0.17,p=0.84) were observed but 
sex influenced the results 
(F1,36=4.51,p=0.04). Female rats of 
control and 0.2 mg/kg of IVM remained 
more time in the open arms than males 
of the same treatments. No differences 
were detected between male and female 
rats treated with 1.0 mg/kg of IVM.  
 Concerning the number of entries 
in the open arms (fig.2C) and the 
number of crosses (fig.2D), no 
differences were observed between sex 
and treatments without interactions 
between factors ( entries in open arms- 
interaction –F2,36=2.85,p=0.07; 
treatments- F2,36=1.10,p=0.32; sex-
F1,36=0.01,p=0.93; number of crosses- 
. interaction –F 2,36=1.15, p=0.33; 
treatments- F2,36 =0.91, p=0.42; sex-
F1,36=3.3, p=0.07). 
 Relative to risk assessment 
(fig.2D) differences were observed 
between treatments   (F2,36= 
4.76,p=0.03) but not relative to sex 
(F1,36=0.03,p=0.97) without interaction 
between factors (F2,36=2.33,p=0.11). 
Female rats of control group showed 
increased risk assessment than male of 
control group. No differences were 
observed between male and female 
treated with both IVM doses. 
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Figure 2- Elevated plus maze behavior of male 
and female rats treated with 0.2 or 1.0 of IVM in 
the juvenile age observed at 45 days age.  A- 
Time in open arms; B-number of entries in the 
open arms; C- number of crossings the center of 
the elevated plus maze; D- number of risk 
assessment. Data are presented as means ± 
SEM. N= 7/group. Two way ANOVA followed by 
the Bonferroni test. *p<0.05 relative to the male 
rat of the same treatment. 
 
Fig.3 illustrates the effects of IVM 
treatment on plasmatic corticosterone 
levels of male and female rats at 45 
days of age. No interaction was 
observed between sex and treatments 
(F2/30=0.55, p=0.5); the sex 
(F1,30=7.35, p=0.01); the treatments 
(F1/30=3.87, p= 0.03) influenced the 
results. The post hoc test indicates an 
increased corticosterone plasmatic level 
in female rats treated with 1.0 of IVM 
relative to male treated with the same 
dose. No differences were observed 
between male and female of control and 
treated with 0.2 mg/kg of IVM dose 
groups. 
 
 
Figure 3- Corticosterone plasmatic levels of 
male and female rats treated with 0.2 or 1.0 of 
IVM in the juvenile age evaluated at 45 days 
age.   Data are presented as means ± SEM. N= 
7/group. Two way ANOVA followed by the 
Bonferroni test. *p<0.05 relative to the male rat 
of the same treatment.  
 
Effects of IVM treatment in male and 
female rats exposed to stress.  
 
 Fig.4 shows the general activity of 
male and female rats exposed to stress 
treated with 0.2 or 1.0 of IVM in the 
juvenile age observed in the OF at 45 
days age.   
 Concerning the total locomotion 
(fig.4A) the two way ANOVA did not 
show interaction between sex and 
treatments (F2,36=0.60, p=0.56), the 
sex influenced the results (F1,36=5.22, 
p=0.03) but not the treatments 
(F2,36=0.76,p=0.48). The Bonferroni 
test indicates an increased total 
locomotion in female of control and 0.2 
mg/kg IVM relative to control and 0.2 
mg/kg IVM groups of males, 
respectively. No differences were 
observed between male and female 
treated with 1.0 mg/kg of IVM.  
 In peripheral locomotion (fig.4B) 
the two way ANOVA did not show 
interaction between sex and treatments 
(F 2,36=1.01, p=0.38); the sex 
influenced the results (F1,36= 7.11, p= 
0.01) but not the treatments 
(F2,36=1.92, p=0.16). The Bonferroni 
test indicates an increased peripheral 
locomotion in female of control and 0.2 
mg/kg IVM relative to control and 0.2 
mg/kg IVM groups of males, 
respectively. No differences were 
observed between male and female 
treated with 1.0 mg/kg of IVM.  
 Relative to immobility (fig.4C) no 
interaction between sex and treatments 
(F2,36 =0.52, p=0.60) was observed;   
the sex (F1,36=0.78, p=0.89) and 
treatments (F2,36=0.11, p=0.38) did not 
influenced the results. 
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Figure 4- General Activity of male and female 
rats submitted to stress, treated with 0.2 or 1.0 of 
IVM in the juvenile age observed in the open 
field at 45 days age.  A- Total locomotion 
frequency; B-peripheral locomotion frequency; 
C- immobility duration (sec). Data are presented 
as means ± SEM. N= 7/group. Two way ANOVA 
followed by the Bonferroni test. *p<0.05 relative 
to the male rat of the same treatment.  
 
  Fig.5 illustrates the effects of 
IVM treatment in male and female rats 
exposed to stress and observed in the 
EPM at 45 days of age.  
 Relative to time in open arms 
(fig.5A), an interaction was observed 
between sex and treatments 
(F2,36=4.22, p=0.02), but not between 
treatments (F2,36=0.64, p=0.43) and 
sex (F 1,36=0.08, p=0.92) 
 Concerning the number of entries 
in the open arms (fig.5B) no differences 
were observed between sex and 
treatments without interactions between 
factors (interaction –      F2,36=2.32, 
p=0.14; treatments- F2,36=0.29, p=0.75; 
sex-F1,36=0.29, p=0.75). 
 Relative to the number of crossing 
(fig.5C), an interaction between factors 
were observed (F2,36=4.21, p=0.02) but 
not between treatments (F2,36=2.25, 
p=0.14) and sex-(F 1,36=0.96, p=0.39). 
The Bonferroni test indicates that female 
of control groups showed increased 
crossings relative to control males.   
 Relative to risk assessment 
(fig.5D) no interaction between sex and 
treatments          (F 2,36=0.50, p=0.61, 
treatments (F2,36=1.22, p=0.28) and 
sex (F1,36=0.31, p=0.73) were 
observed. 
 
Figure.5 -  Elevated plus maze behavior of male 
and female rats exposed to stress and treated 
with 0.2 or 1.0 of IVM in the juvenile age 
observed at 45 days age.  A- Time in open arms; 
B-number of entries in the open arms; C- 
number of crossings the center of the elevated 
plus maze; D- number of risk assessment. Data 
are presented as means ± SEM. N= 7/group. 
Two way ANOVA followed by the Bonferroni 
test. *p< 0.05 relative to the male rat of the same 
treatment.  
 
 Fig.6 illustrates the effects of IVM 
treatment on plasmatic corticosterone 
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levels of male and female rats exposed 
to stress at 45 days of age. No 
interaction between sex and treatments 
(F2/38 = 0.55, p= 0.5), sex (F1, 38 = 
0.15, p=0.70) and treatments (F2/38 = 
2.23, p = 0.12) were observed. 
 
 
Figure 6- Corticosterone plasmatic levels of 
male and female rats submitted to stress and 
treated with 0.2 or 1.0 of IVM in the juvenile age 
evaluated at 45 days age.   Data are presented 
as means ± SEM. N= 7/group. Two way 
ANOVA.  
 
DISCUSSION  
 Sex differences in OF activity 
appear at defined developmental stages 
(11) and are maintained in adult life. 
Females are more active than males 
(ANDERSON, 1940; BROADHURST, 
1957) and it has been suggested that 
these differences in behavior reflect sex 
differences in emotionality or 
susceptibility to the arousal of fear, 
males being held to be more fearful than 
females (GRAY, 1971). In 
developmental studies, these 
differences were shown to emerge in the 
peripuberal period at 50-60 days of age 
(BLIZARD; LIPPMAN; CHEN, 1975). 
 Our results corroborated with these 
data because a sexual dimorphic 
behavior of male and female of control 
groups was observed at 45 days of age 
where female rats explore more the OF 
than males. In fact, the total and 
peripheral locomotion is higher in female 
than in males of control groups with 
reduced immobility in females. However, 
these differences were attenuated in rats 
treated with 0.2 mg/kg of IVM (no 
differences in immobility) and 
disappears after 1.0 mg/kg.  
 Decreased locomotion frequency 
and increased immobility time and vice-
versa are interpreted in the OF as 
interference with motor/exploratory 
behavior. These data suggest that 
female rats of control groups showed 
increased motor/exploratory behavior. 
Studies in the OF take the ambulation 
and defecation as a double that express 
emotionality mainly when studies were 
performed of sexual dimorphism. 
Because of the criticisms raised against 
the defecation score as a measure of 
the central effects of drugs(CUNHA; 
MASUR, 1978), in the present 
experiment we did not measured 
defecation but the peripheral locomotion.  
Typically, rats are more active and 
remain longer in the periphery in the OF 
in comparison to the central areas, 
mainly in the first session, a preference 
that has been interpreted as being 
determined by thigmotaxis (VALLE, 
1970). Thigmotaxis (the tendency to 
remain close to vertical surfaces) ay 
related to the grade of  aversion to open 
areas (LAMPREA et al., 2008). Our 
control group showed increased 
peripheral locomotion in the OF also 
suggesting increased aversion to open 
areas of the OF. 
 Treatment  at 30 and 45 days of 
age with IVM reduced the sexual 
dimorphism,  mainly in the high dose, by 
reduced the locomotor of female rats in 
the OF. Previously we observed that 
IVM reduces sexual behavior in female 
rats in natural estrus (physiological 
condition) in normal cycling rat or 
induced in intact female rats with 
estradiol valerate (MOREIRA; 
BERNARDI; SPINOSA, 2014). In cows, 
administration of IVM at therapeutic 
dose induces a sharp decrease in serum 
FSH, LH and estradiol and increased 
serum progesterone, prolactin and 
cortisol that return to normal levels on 
the 90th day following injection. Serum 
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sex hormones binding globulin and 
testosterone were not affected 
throughout the experiment (SADEK; 
SHAHEEN, 2015). However, a 
therapeutic IVM dose had no detrimental 
effect on the reproductive performance 
of ewes during the breeding season. In 
the present study IVM was administered 
in prepubertal and pubertal ages, critical 
periods of the brain sexual activation 
(WILSON; DAVIES, 2007). Thus it is 
possible that IVM exposure during these 
periods, by affecting hormonal milieu of 
male and female rats, affected the 
sexual dimorphism on behavioral 
responses observed in the OF. 
 Another hypothesis to explain the 
reduced sexual dimorphism here 
observed is the involvement of the 
GABAergic system on  the regulation of 
the hypothalamic –pituitary-adrenal axis 
(HPA) or −gonadal (HPG) axis 
(CULLINAN; ZIEGLER; HERMAN, 
2008). Activation or blockade of the 
GABA-A receptors during early life 
induces brain and behavioral 
abnormalities in adulthood, and may 
alter physiological phenotypes in a sex-
dependent manner in mice (SALARI; 
AMANI, 2017). Thus, IVM acting as 
agonists at GABA-A receptors and 
stimulating GABA release (DAWSON et 
al., 2000) could affect the hormone 
regulating sexual activation during 
puberty. 
  Also in the EPM, these behavioral 
differences between male and female 
rats were observed. Female rats showed 
a reduced aversion for the open arms in 
EPM compared to male rats and tended 
to make more number of risk 
assessment indicating a higher overall 
level of activity in this test. These 
findings are in agreement with previous 
report which suggested that female 
Wistar rats were less anxious than male 
Wistar rats based on their performance 
in an EPM test(IMHOF et al., 1993). 
Treatment with 0.2 mg/kg of IVM did not 
modify the time in open arms of female 
but reduced the risk assessment. In 
male and female rats treated with 1.0 
mg/kg this sexual dimorphism 
disappears.  
 No sexual dimorphism was 
observed between control and rats 
treated with 0.2 mg/kg of IVM on 
corticosterone plasmatic levels. These 
sexual differences were observed in rats 
treated with 1.0 mg/kg where female had 
increased levels in this hormone relative 
to male rats. This increased in 
corticosterone levels could explain the 
reduced time in the open arms of female 
treated with 1.0 mg/kg of IVM relative to 
males of the same treatment, and the 
lack of sexual dimorphism observed in 
the EPM at this dose.   
     Stress exposure had few effects 
on sexual dimorphism of male and 
female rats observed in the OF.  In fact, 
control and 0.2 mg/kg of IVM showed a 
clear dimorphic behavior in total and 
peripheral locomotion while no 
differences were observed between 
male and female rats treated with 1.0 
mg/kg of IVM. Only the sexual 
dimorphism in immobility behavior of 
control male and female disappear. 
Thus, our model of stress did not 
affected the sexual dimorphism effects 
of IVM in the OF behavior. 
 The present data indicate sex 
differences, on behavioral effects, of 
IVM administered in early and middle 
adolescence. In both sexes of stressed 
and non-stressed rats, observed in the 
OF, female rats are more susceptible 
than male rats, to the effect of the drug 
in the OF. 
 In the EPM, a great variability was 
observed in female responses relative to 
males but no differences were observed 
in all parameters between sexes, except 
in the number of crosses in the control 
group. Female control rats crossed more 
the center of the EPM than male rats. 
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 Concerning the corticosterone 
levels of stressed rats, no differences 
were observed between sexes of all 
groups. Thus, in the EPM and 
corticosterone levels, stress reduced the 
sexual dimorphism while no 
interferences in the OF behavior was 
observed.  
  It was found that the adult-like 
ACTH stress response, from the 
pituitary, develops during the later 
stages of adolescence (PND46 to 
PND59), while the corticosterone 
response from the adrenal gland 
changes earlier between the PND30 to  
PND40 (FOILB; LUI; ROMEO, 2011). 
These results indicate that shifts in 
hormonal stress responses occur 
throughout adolescence and that each 
gland along this neuroendocrine axis 
displays a unique developmental 
trajectory(ROMEO et al., 2016). Thus, in 
our study, the restraint stress was 
applied in middle adolescence age of 
rats, when the ACTH stress response 
from the pituitary was developed, to 
verify the effects of IVM in this phase. In 
addition, gender is one major variable 
related to differential vulnerability to 
stress. Most of the data about the effects 
of stress, during early period of life and 
adolescence, were performed in male 
rats. Few studies relative to females and 
chronic stress during adolescence 
reported a greater susceptibility to 
outcomes of  female rats  than males  
(DALLA et al., 2005;ROMEO et al., 
2016; MCCORMICK; SMITH; 
MATHEWS, 2008). Moreover, 
Traslaviña et al., (2014) reported that 
both, adult behavior and the 
glucocorticoid stress response , are 
affected differently in males versus 
females by adolescent stress. The 
duration of stressors had a greater effect 
on corticosterone and progesterone 
response in males, whereas the nature 
of the stressor had a greater effect on 
exploratory behavior in females. Thus, 
we suggest that our stress model 
applied during the juvenile period 
affected mainly female’s behavioral 
responses after IVM high dose. Because 
IVM is used in children and adolescents, 
the present data could have clinical 
implications relative to gender effects. 
 
CONCLUSIONS 
  
A lack of sexual dimorphism was 
observed in the OF and EPM tests after 
the IVM high dose administered during 
the juvenile period. We attribute this 
effect by a disruption in female rats in the 
EPM to the high levels of corticosterone. 
The 0.2 mg/kg/ did not affected the 
sexual dimorphism in both behavioral 
tests. Restraint stress was unable to alter 
the effects of both IVM doses in the OF 
behavior but, in the EPM,  the sexual 
behavioral dimorphism was impaired in 
controls and experimental groups as well 
as no differences were observed in the 
corticosterone plasmatic levels of male 
and female of all groups. 
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